GES is a leading manufacturer of therapeutic cannabis products derived from medical-grade cannabis flowers, meticulously designed for pharmaceutical applications. Our state-of-the-art facility specializes in extracting and purifying primary bulk cannabinoids, including Δ9-THC and CBD, sourced from our trusted network of high-quality cultivators.
Driven by extensive research and development programs, we've developed proprietary, chemo-type-specific API formulations that align with the therapeutic potential of medical cannabis. Our manufacturing processes adhere to strict pharmaceutical Good Manufacturing Practice (GMP) standards and incorporate advanced pharmaceutical manufacturing technologies to ensure consistency and standardization.
At GES, we harness nature's abundant active therapies and refine them through modern scientific discoveries, delivering innovative, reliable, and effective therapeutic cannabis solutions.
Company Details
- Employees
- 47
- Founded
- -
- Address
- London, Gb
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- geslabs.com
- Keywords
- Good Manufacturing Practise, GMP, Pharmaceuticals, Medicine, Cannabinoids, Alkaloids, Manufacturing, Engineering, Drug Development.
- HQ
- London
Geslabs Questions
Geslabs's website is geslabs.com
Geslabs's LinkedIn profile is https://uk.linkedin.com/company/geslabs
Geslabs has
47 employees.
View email and phone details for 47
employees at Geslabs.
Geslabs's industry is
Pharmaceutical Manufacturing
Geslabs's top competitors are
Nautilus Pharma Manufacturing Specialists,
Cipla Africa,
Wegrow Cannabis Lesotho,
Mg Health Limited,
Smt Labs,
Safricanna,
Microchem By Agq Labs,
Afriplex Pty Ltd,
Psylabs,
Biovac.
Geslabs's categories are Pharmaceutical Manufacturing
Geslabs's founding year is 2018
